Apr 19, 2010
SuppreMol Receives U.S. Orphan Drug Designation for SM101

Apr 12, 2010
SuppreMol initiates Phase Ib/IIa clinical trial with its lead candidate SM101

Feb 08, 2010
SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing

September 15-17, 2010
BioPharma America 2010, Boston, MA, USA

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources

Prof. Peter Buckel im Video-Interview

SuppreMol GmbH is a young biotechnology company located in the IZB-Martinsried and is focused on the development of novel therapeutics for the treatment of autoimmune diseases. Its highly interdisciplinary team of 14 employees is involved in research as well as clinical development actities.

 

Current open positions: